tiprankstipranks
Advertisement
Advertisement

Synergy CHC Amends Term Loan, Issues Contingent Warrant

Story Highlights
  • Synergy CHC tightened loan terms and covenants on March 24, 2026, adding equity-raise triggers, PIK interest options, and stricter EBITDA and leverage tests that heighten liquidity and balance sheet pressure.
  • Alongside the amendment, Synergy CHC issued a highly dilutive default-triggered warrant to a lender, bolstering creditor protections but creating potential future dilution subject to shareholder approval limits.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Synergy CHC Amends Term Loan, Issues Contingent Warrant

Claim 30% Off TipRanks

An announcement from Synergy CHC ( (SNYR) ) is now available.

On March 24, 2026, Synergy CHC amended its term loan credit agreement with ACP Agency and lenders, revising the amortization schedule, interest mechanics, pricing, leverage and EBITDA covenants, and rules for using equity issuance proceeds. The company faces stepped‑up interest margins if it fails to raise at least $10 million in new equity by September 30, 2026, gains flexibility to pay certain near‑term interest in kind, and must meet new minimum EBITDA thresholds and tightened leverage tests that could pressure its liquidity and balance‑sheet management.

The amendment also restricts Synergy CHC’s ability to elect Term SOFR‑based interest until it makes at least $4 million of principal prepayments and raises the ownership threshold in the change‑of‑control definition to more than 40%. In connection with the amendment, the company issued a warrant on March 24, 2026 to Acme Credit Partners Fund I, LP for up to 3 million shares at a nominal exercise price, exercisable only upon a qualified event of default and subject to a 19.9% ownership cap pending shareholder approval, a structure that strengthens lender protections while introducing potential future dilution for equity holders.

The most recent analyst rating on (SNYR) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Synergy CHC stock, see the SNYR Stock Forecast page.

Spark’s Take on SNYR Stock

According to Spark, TipRanks’ AI Analyst, SNYR is a Neutral.

The score is held back primarily by balance sheet stress (negative equity) and negative recent cash generation, which elevate financing risk despite improved profitability. Technical indicators also point to weak momentum below major moving averages. These are partially offset by a low P/E valuation and an earnings call that showed revenue growth and margin improvement but weaker net income/EPS and higher operating cash usage.

To see Spark’s full report on SNYR stock, click here.

More about Synergy CHC

Synergy CHC Corp. operates in the consumer health and wellness sector, focusing on branded over‑the‑counter products and related consumer healthcare offerings. The company relies on term loan financing to support its operations and capital needs, making its credit arrangements and equity‑funding plans important to its capital structure and financial flexibility.

Average Trading Volume: 27,266

Technical Sentiment Signal: Sell

Current Market Cap: $13.16M

See more insights into SNYR stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1